Latest News

Weight-loss drug developers line up to tap market worth $150 billion

Novo Nordisk's Wegovy and Eli Lilly's Zepbound are so far the leaders in the weightloss drug market, which is approximated to be worth about $ 150 billion by the early 2030s.

But there are several other drug developers aiming to sign up with the bandwagon. The following is a list of openly noted business targeting the next huge smash hit chance:

NOVO NORDISK

Novo's most current prospect, amycretin, helped obese patients attain 13.1% weight loss after 12 weeks of treatment. The information compares to a weight loss of about 6% after 12 weeks in a trial for Wegovy.

Novo said it prepares to begin a mid-stage study for amycretin in the second half of the year with results due in early 2026.

Novo Nordisk in August reported data from a large study, which showed Wegovy also had a clear cardiovascular advantage. Wegovy, which utilizes the same active ingredient as Novo's diabetes drug Ozempic, was authorized in 2021.

The drugmaker in June reported late-stage trial data from a. high-dose oral version of its drug, semaglutide, assisting. obese or overweight grownups lose 15% of their body weight, which. remained in line with recent outcomes for other experimental obesity. pills.

The business stated in February it will purchase three of Catalent's. fill-finish websites - in Anagni, Italy; Brussels, Belgium; and. Bloomington, Indiana - from Novo Holdings for $11 billion to. help boost its production of Wegovy. The sites will be acquired. after Novo Holdings finishes its Catalent acquisition.

ELI LILLY

Eli Lilly's weight-loss treatment, Zepbound, got the green. light from U.S. and UK regulators in November, leading the way. for an effective brand-new rival to Novo's Wegovy.

The company reported $175.8 million in sales of Zepbound in. the very first few weeks of its launch in December. The drug,. chemically called tirzepatide, has been offered as Mounjaro. for type 2 diabetes given that 2022 and was utilized off-label for. weight-loss.

Lilly stated in June a mid-stage trial of its next-generation. weight problems drug prospect, a once-weekly injection of retatrutide,. resulted in a weight reduction of approximately 24.2% after 48 weeks.

PFIZER

Pfizer stated in December it was stopping even more. trials of a twice-daily variation of its oral weight-loss drug,. danuglipron.

The choice comes after many clients in a mid-stage trial. left with high rates of side effects such as queasiness and. vomiting.

The company stated it will instead concentrate on a once-daily,. modified release variation of danuglipron. Information on how this. version communicates with the body is expected next year.

In June, Pfizer had scrapped the advancement of its. once-a-day tablet due to concerns over liver security.

ROCHE AND CARMOT THERAPIES

Roche obtained CT-388 as part of its $2.7 billion. buyout of Carmot Therapies. Carmot's once-a-week injection. comes from the same class as Eli Lilly's Mounjaro, or. Zepbound.

The newly gotten drug prospect has completed early-stage. trials and is prepared to be tested on human beings in the second of. three trial stages, Roche stated.

AMGEN

Amgen's experimental obesity drug, AMG133, in. November revealed a mean weight reduction of 14.5% after 12 weeks of. treatment at the greatest monthly dosage.

ALTIMMUNE

Altimmune in November said its drug prospect,. pemvidutide, helped reduce weight by 15.6% typically and showed. continued weight reduction at the end of treatment in a mid-stage. trial.

Nevertheless, patients likewise experienced nausea and vomiting of. moderate and moderate seriousness.

VIKING THERAPEUTICS

Viking Rehabs stated in February its. speculative drug, VK2735, assisted clients with obesity achieve. significant weight-loss in a mid-stage study.

VK2735 assisted patients accomplish as much as 14.7% mean weight reduction. after 13 weeks of treatment, according to data from the study,. which had enrolled 176 overweight adults with a minimum of one. weight-related comorbidity.

ZEALAND PHARMA

Denmark's Zealand Pharma and Boehringer. Ingelheim's speculative obesity treatment attained approximately 14.9%. weight loss in a mid-stage trial in May.

OPKO HEALTH

Opko Health has finished a mid-stage trial of its. weight problems drug, pegapamodutide, which it anticipates will have less. side effects.

STRUCTURE THERAPEUTICS

Structure Therapeutics stated its speculative oral. weight problems drug helped reduce weight by 6.2% usually at the end. of 12 weeks in a mid-stage research study.

(source: Reuters)